Neurocrine Biosciences Inc. (NBIX)
-NasdaqGS 12.88 
0.18(1.42%) 4:00PM EDT|After Hours
:
12.88 0.00 (0.00%) 4:32PM EDT
| Prev Close: | 12.70 |
|---|
| Open: | 12.82 |
|---|
| Bid: | 12.80 x 300 |
|---|
| Ask: | 14.97 x 200 |
|---|
| 1y Target Est: | 15.25 |
|---|
| Beta: | 0.75 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 12.82 - 13.35 |
|---|
| 52wk Range: | 6.72 - 14.06 |
|---|
| Volume: | 707,223 |
|---|
| Avg Vol (3m): | 550,545 |
|---|
| Market Cap: | 859.51M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.09 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Coverage initiated on Neurocrine Biosci by OppenheimerBriefing.com(Wed 12:15AM EDT)
- Neurocrine Biosciences initiated with an Outperform at Oppenheimertheflyonthewall.com(Tue, Jun 18)
- Neurocrine's CEO Presents at Deutsche Bank 38th Annual dbAccess Health Care Conference (Transcript)at Seeking Alpha(Thu, May 30)
- 'Mad Money' Lightning Round: Hold on to Sprintat TheStreet(Thu, May 30)
- Lightning Round: Sprint, Annaly Capital & Moreat CNBC(Wed, May 29)
- [video] Lightning Roundat CNBC(Wed, May 29)
- Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare ConferencePR Newswire(Wed, May 29)
- NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Tue, May 28)
- Commit To Buy Neurocrine Biosciences At $9, Earn 28.8% Annualizedat TheStreet(Fri, May 24)
- Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care ConferencePR Newswire(Thu, May 23)
- Neurocrine Biosciences' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Thu, May 16)
- A Look At Neurocrine's VMAT-2 Inhibitor As Phase IIb Data Nearsat Seeking Alpha(Fri, May 10)
- NEUROCRINE BIOSCIENCES INC FinancialsEDGAR Online Financials(Fri, May 10)
- Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care ConferencePR Newswire(Thu, May 9)
- Neurocrine Biosciences Inc. Stock Downgraded (NBIX)at TheStreet(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 19.89 |
|---|
| Ex-Dividend Date: | 29-Dec-95 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.78 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -0.24 |
|---|
Business Summary
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
View More